Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's make-or-break moon shot - 2Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- 3Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- 4Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- 5Nearly half of reindeer have been wiped out and armadillos are in Iowa. Here’s how animals are weathering warming holidays
- Fundamental Archives for Beginning Your Business
- How did I get my own unique set of fingerprints?
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- Vote In favor of Your Favored Occasion Arranging Administration
- Medical team successfully delivers baby and removes massive tumor
- Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- Israeli forces kill one person in series of attacks on southern Lebanon
- Figure out How to Take part in Open Conversations Around 5G Pinnacles
- 1,000-mile Saharan dust storm, from the sky and from the ground
